Jiangsu (SH:688426)2025-10-30 08:05Financial Performance - Revenue for Q3 2025 reached ¥52,455,562.72, an increase of 68.47% compared to the same period last year[3] - Total profit for Q3 2025 was -¥21,249,963.37, representing a decrease of 54.96% year-on-year[3] - Net profit attributable to shareholders for Q3 2025 was -¥20,251,462.35, a decline of 55.58% compared to the previous year[3] - Operating cash flow for Q3 2025 was -¥22,168,904.60, a decrease of 34.03% year-on-year[3] - Total operating revenue for the first three quarters of 2025 reached ¥139,574,234.46, a significant increase from ¥98,283,588.99 in the same period of 2024, representing a growth of approximately 42%[18] - The operating profit for the first three quarters of 2025 was reported at -¥79,256,667.56, an improvement compared to -¥104,752,492.00 in 2024[19] - Net profit for the first three quarters of 2025 was -¥78,096,679.32, compared to -¥95,907,697.78 in the same period of 2024, indicating a reduction in losses[19] - The total comprehensive income attributable to the parent company was -76,162,854.28 CNY, compared to -95,645,454.09 CNY in the previous period, showing an improvement[20] - The company reported a basic and diluted earnings per share of -0.69 CNY, an improvement from -0.86 CNY in the prior period[20] Research and Development - R&D expenses totaled ¥18,092,442.60 in Q3 2025, down 30.50% from the previous year[4] - R&D expenses accounted for 34.49% of revenue in Q3 2025, a decrease of 49.11 percentage points year-on-year[4] - Research and development expenses for the first three quarters of 2025 amounted to ¥58,902,293.52, down from ¥72,049,404.79 in 2024, showing a decrease of approximately 18%[18] - The company optimized R&D resource allocation, focusing on market-oriented projects to enhance efficiency[8] Assets and Liabilities - Total assets at the end of Q3 2025 were ¥1,550,833,825.96, a decrease of 4.16% from the end of the previous year[4] - Total liabilities increased to ¥141,692,635.09 from ¥131,788,713.04, marking an increase of about 7%[14] - The total equity attributable to shareholders decreased to ¥1,390,519,558.42 from ¥1,465,785,417.74, reflecting a decline of approximately 5.1%[14] - Cash and cash equivalents included in current assets totaled ¥1,087,753,273.02, compared to ¥833,404,226.85 in the previous period, indicating a growth of about 30.5%[15] - The company reported a decrease in short-term borrowings to ¥10,007,777.78 from ¥6,005,600.00, reflecting a strategic reduction in debt[14] Shareholder Information - The total number of common shareholders at the end of the reporting period is 3,905[10] - Beijing Kangwei Century Biotechnology Co., Ltd. holds 50,400,000 shares, accounting for 44.80% of total shares[10] - Taizhou Kangwei Co-Creation Enterprise Management Consulting Partnership holds 21,600,000 shares, representing 19.20% of total shares[10] - The top ten shareholders do not include any shares lent through margin trading[12] - The company has no significant changes in shareholder structure compared to the previous period[12] Cash Flow - The company's cash and cash equivalents as of September 30, 2025, amount to ¥184,205,974.30, down from ¥255,466,049.27 as of December 31, 2024[12] - The net cash flow from operating activities was -71,824,555.68 CNY, an improvement from -92,827,326.52 CNY year-over-year[21] - Cash received from the sale of goods and services increased to 126,143,516.94 CNY, up from 90,526,995.55 CNY in the same period last year, representing a growth of approximately 39.2%[21] - The company incurred operating cash outflows totaling 229,309,685.83 CNY, compared to 189,799,092.17 CNY in the previous year[21] - The company received cash inflows from investment activities totaling 1,219,429,294.81 CNY, compared to 707,660,113.86 CNY in the previous year[21] - The company’s cash outflows from financing activities were 14,202,559.75 CNY, compared to 54,328,194.97 CNY in the previous year, indicating a reduction in financing costs[21] Operational Highlights - The increase in revenue was primarily driven by significant growth in nanopore sequencing services[8] - There are no other important reminders regarding the company's operational situation during the reporting period[12] - The company did not execute any mergers or acquisitions during the reporting period[20]